Robert Talac: Is PRP Truly Autologous?
Robert Talac, Medical Director at Renaxis Regenerative Orthopedic Center, shared a post on LinkedIn:
“PRP Is Not Fully Autologous.
We should probably talk about that.
I’ve been in regenerative medicine for over 30 years.
For most of that time, PRP was widely accepted as the gold standard of autologous biologics.
I want to challenge that.
Here’s what’s actually in a standard PRP preparation:
- Citrate or EDTA anticoagulants (not from the patient)
- Bovine thrombin as an activator (not from thepatient)
- Calcium chloride to trigger clotting (not from the patient)
None of these are autologous. And it’s not a minor footnote.
EDTA and citrate disturb natural ionic homeostasis and alter cytokine profiles.
Bovine thrombin carries a documented immunogenicity risk, potentially triggering antibody responses against the patient’s own clotting factors.
This is not a fringe concern. It’s in the published data.
Platelet-Rich Fibrin (PRF), by contrast, uses no anticoagulant.
- Blood is drawn and immediately centrifuged.
- Clotting occurs through physiologic thrombin alone.
- No external activator, no foreign additive, no biochemical modification.
One caveat worth naming: many commercial PRF kits use silica or silicone-coated tubes as clot activators.
Those are foreign materials, too.
Which is why I use plain glass tubes (Bio-PRF) – the only truly additive-free option.
The result?
A dense autologous platelet-rich fibrin matrix. Nothing added. Nothing altered.
We’ve spent decades debating PRP activation protocols, platelet concentrations, and leucocyte ratios. Maybe the more important question is simpler:
If autologous therapy is the goal – is PRP actually”

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC